New drug cocktail targets tough breast cancer
NCT ID NCT03901469
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs, ZEN003694 and talazoparib, in people with triple-negative breast cancer who do not have BRCA gene mutations. The trial aimed to see if the combo could shrink tumors or stop them from growing. It included 115 participants but was terminated early, so final results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ZEN003694 (a BET inhibitor) combined with talazoparib (a PARP inhibitor)
What this could lead to
If successful, this combination could offer a new treatment option for triple-negative breast cancer patients who don't have BRCA mutations.
What could go wrong
The trial was terminated early, so results are limited. It was a phase 2 study, meaning it's still early and may not lead to a proven treatment. Side effects from the drug combination are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affliated Hospital of Jining Medical University
Jining, Shandong, 272000, China
-
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Emory University Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Hunan Cancer Hospital
Changsha, Hunan, 410000, China
-
Institut Jules Bordet
Anderlecht, 1070, Belgium
-
MD Anderson
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
START Madrid
Madrid, 28050, Spain
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510289, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
Tennessee Oncology (Sarah Cannon)
Nashville, Tennessee, 37203, United States
-
The First Affiliated Hosptial of Bengbu Medical College
Bengbu, Anhui, 233000, China
-
The Second People's Hospital of Neijiang
Neijiang, Sichuan, 641100, China
-
Tianjing Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300060, China
-
UZ Leuven
Leuven, 3000, Belgium
-
University of Kansas Cancer Center
Westwood, Kansas, 66203, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Vall d'Hebron Institute of Oncology (VHIO)
Barcelona, 08035, Spain